4.05
5.59%
-0.24
After Hours:
4.05
Inotiv Inc stock is currently priced at $4.05, with a 24-hour trading volume of 327.90K.
It has seen a -5.59% decreased in the last 24 hours and a -59.66% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.33 pivot point. If it approaches the $3.84 support level, significant changes may occur.
Previous Close:
$4.29
Open:
$4.29
24h Volume:
327.90K
Market Cap:
$104.45M
Revenue:
$585.17M
Net Income/Loss:
$-33.21M
P/E Ratio:
-0.3052
EPS:
-13.27
Net Cash Flow:
$4.04M
1W Performance:
-6.25%
1M Performance:
-59.66%
6M Performance:
+104.55%
1Y Performance:
-24.86%
Inotiv Inc Stock (NOTV) Company Profile
Name
Inotiv Inc
Sector
Industry
Phone
765 463 4527
Address
2701 Kent Avenue, West Lafayette
Inotiv Inc Stock (NOTV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
Jan-11-23 | Upgrade | Lake Street | Hold → Buy |
Nov-18-22 | Downgrade | Lake Street | Buy → Hold |
Oct-04-22 | Initiated | Jefferies | Buy |
Jan-31-22 | Initiated | Lake Street | Buy |
Sep-20-21 | Initiated | Craig Hallum | Buy |
View All
Inotiv Inc Stock (NOTV) Latest News
Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors
Zacks Investment Research
Is Inotiv (NOTV) a Great Value Stock Right Now?
Zacks Investment Research
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Zacks Investment Research
Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going
Zacks Investment Research
Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy?
Zacks Investment Research
Inotiv Inc Stock (NOTV) Financials Data
Inotiv Inc (NOTV) Revenue 2024
NOTV reported a revenue (TTM) of $585.17 million for the quarter ending December 31, 2023, a -0.18% decline year-over-year.
Inotiv Inc (NOTV) Net Income 2024
NOTV net income (TTM) was -$33.20 million for the quarter ending December 31, 2023, a +90.27% increase year-over-year.
Inotiv Inc (NOTV) Cash Flow 2024
NOTV recorded a free cash flow (TTM) of $4.04 million for the quarter ending December 31, 2023, a +108.00% increase year-over-year.
Inotiv Inc (NOTV) Earnings per Share 2024
NOTV earnings per share (TTM) was -$1.30 for the quarter ending December 31, 2023, a +90.25% growth year-over-year.
About Inotiv Inc
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Cap:
|
Volume (24h):